Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
July 2026—Roche’s new Cobas Mass Spec solution will be on display this month at the ADLM meeting, as will Diasorin’s new Liaison Nes, Siemens Healthineers’ Atellica DT 250, and much more. CAP TODAY publisher Bob McGonnagle spoke online in late May with representatives of Roche, Diasorin, Sebia, and Siemens Healthineers about how their instruments will solve some of laboratories’ pressing problems. The conversation follows.
June 2026—Instrumentation for all laboratory testing sites—large and small—was the roundtable topic on April 21 when representatives of Roche, Beckman Coulter, and Siemens Healthineers met online with Moira Larsen, MD, MBA, of MedStar, and Joe Baker of Baylor Scott & White. CAP TODAY publisher Bob McGonnagle led, with questions about, among other things, AI, testing consolidation, what laboratories expect of vendors, and what laboratories are willing to contribute to the partnership. “We’re happy to help figure out what the bugs are,” Baker says of new instrumentation.
May 2026—The fast-changing world of sequencing was the topic that a panel of pathologists and industry representatives dug into in a Feb. 27 online roundtable, led by CAP TODAY publisher Bob McGonnagle.
April 2026—Laboratory and pathology billing face challenges from reimbursement threats, downcoding, denials, and prior authorizations.
March 2026—A roundtable discussion focused on improving workflow efficiency in urinalysis, highlighting the potential of AI to enhance reflex testing by integrating test results with EHR data.
February 2026—Cybersecurity and image management are key concerns for laboratories adopting digital pathology and AI. While cloud-based systems offer enhanced security and scalability, onboarding new vendors and instruments remains challenging due to stringent security requirements and potential vulnerabilities.
January 2026—The Association for Diagnostics and Laboratory Medicine released new guidance discouraging clot-based testing in patients receiving direct oral anticoagulants (DOACs).
November 2025—A roundtable discussion on laboratory information systems (LIS) highlighted the challenges labs face in meeting increasing demands with limited resources. The conversation emphasized the need for improved interoperability, automation, and flexibility in LIS to address complex testing workflows and workforce shortages.
June 2025—Chemistry and immunoassay analyzers—the customer input that shapes their development and the laboratory acquisition process and timeline. That and more, including the IT obstacles and solutions, were the focus of a roundtable, led by CAP TODAY publisher Bob McGonnagle. He spoke with Moira Larsen, MD, MBA, of MedStar Health; Joe Baker of Baylor Scott & White; and representatives of Beckman Coulter, Roche, and Siemens Healthineers. Read about their April 15 online conversation.
May 2025—In-house or send out, small panel or large, ease of use, getting the most information possible from a sample and doing it fast—that was at the center of a March 17 conversation on next-generation sequencing, led by CAP TODAY publisher Bob McGonnagle. “More and more patients need this testing faster and faster,” Jeremy Segal, MD, PhD, of the University of Chicago, said. What he and four industry executives told us in the online roundtable follows.
